Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepoloxamer in chronic heart failure
NCT02596477Phase 2Terminated
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vepoloxamer in chronic heart failure (CHF), sponsored by Mast Therapeutics, Inc.. Started Oct 2015; status: terminated.
02
Drugs
vepoloxamer
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT02596477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596477.